Verisante Wins Prism Award at SPIE Photonics West Gala; Prestigious Honour Comes as the Company Begins to Place the Innovative

Verisante Wins Prism Award at SPIE Photonics West Gala; Prestigious Honour 
Comes as the Company Begins to Place the Innovative Skin
Cancer Detector at Clinics Across Canada and Europe 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/07/13 -- Verisante
Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the
"Company" or "Verisante"), a leader in cancer detection technology,
announced today that the Company has won a 2013 Prism Award in the
Life Sciences and Biophotonics category for Aura(TM), a revolutionary
skin cancer detection device. The winners were announced at an Awards
banquet on February 6, 2013 in San Francisco. 
"It is very gratifying to be recognized as an industry leader for our
innovative and disruptive technology," said Thomas Braun, the
Company's President & CEO, who accepted the award on behalf of the
Company. "Many years of hard work and scientific research have
contributed to this honour, and we would like to recognize the
dedication of the BC Cancer Agency, the Skin Care Centre at Vancouver
General Hospital, the University of British Columbia and the
Vancouver Coastal Health Research Institute, whose collaboration in
the development of this technology provided Verisante with the
opportunity to bring Aura(TM) to full commercialization." 
First sales of Aura(TM) were recently announced through the Company's
exclusive distributors, Clarion Medical Technologies in Canada, and
bo pharma and Laserwelt in Europe. The Company expects to begin
placing the first nine of the initial production units that have been
sold in clinics across Canada and Europe in the next several weeks.
The Company will keep the remaining unit for demonstration purposes
at its head office in Vancouver. 
Verisante Aura(TM) is indicated for use for the evaluation of skin
lesions that may be clinically suspicious for melanoma, squamous cell
carcinoma and/or basal cell carcinoma when a medical professional
chooses to obtain additional information to rule out one of the above
conditions before making a final decision to biopsy. Aura(TM) is a
non-invasive optical system that uses Raman spectroscopy to
biochemically analyze the skin, providing immediate and accurate
results. The device will help to automate the current process of
diagnosis, allowing rapid 
scanning of the 20 to 40 skin lesions on
at-risk individuals, improving patient outcomes and comfort. 
To view photos from the Prism Awards ceremony, visit Verisante's
Facebook page at: http://www.facebook.com/verisante 
About the 2013 Prism Awards 
The Prism Awards, named the "Photonics Oscar" by OptecNet
Deutschland, is a celebration of the best of our industry. It takes
place every year in conjunction with SPIE Photonics West in San
Francisco, California. 
The Prism Awards for Photonics Innovation is a leading international
competition that honors the best new photonic products on the market.
Over the years, the Prism Awards has received applications from more
than 35 countries across the globe. Applications are judged by a
panel of leading industry experts, venture capitalists, luminaries
and visionaries. The finalists and winners that are ultimately chosen
(from General Electric, Agilent, Hamamatsu to Swamp Optics, Optotune,
WiTec) reflect the diversity of the program. 
SPIE Photonics West is the world's largest and most influential
photonics and optics event with over 1500 companies exhibiting and
20,000 attendees. 
To find out more about the Awards, visit the website at:
http://www.photonicsprismaward.com 
About Verisante Technology, Inc. 
Verisante is a medical device company committed to commercializing
innovative systems for the early detection of cancer. The Verisante
Aura(TM) for skin cancer detection and the Verisante Core(TM) series
for lung, colon and cervical cancer detection utilize a proprietary
cancer detection platform while the operating software and probe
technology are unique to each device. The cancer detection platform
was developed by the BC Cancer Agency and tested and refined at the
Skin Care Centre at Vancouver General Hospital. This exclusive
platform technology allows Verisante to develop and offer a range of
compact, non-invasive cancer detection devices that offer physicians
immediate results for many of the most common cancers. Aura(TM) has
been approved for sale in Canada, Europe and Australia. The Core(TM)
has not yet been approved for sale. 
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of
What's New Award" for 2011, and Verisante Core(TM) was named one of
the top 10 cancer breakthroughs of 2011 by the Canadian Cancer
Society. 
Website: www.verisante.com 
YouTube: www.youtube.com/verisante  
Twitter: www.twitter.com/verisante 
Facebook: www.facebook.com/verisante 
Forward-Looking Statements 
This release contains forward-looking statements, including, but not
limited to, statements regarding the future commercialization of
medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks, and
the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties. 
The TSX Venture Exchange has neither approved nor disapproved of the
contents of this press release. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this press release. 
Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com
 
 
Press spacebar to pause and continue. Press esc to stop.